ACADACADIA Pharmaceuticals Inc.
Price
-19%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, price roughly fair, growth steady, the market undecided.
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $308M in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 91% and net income of $32M (10% of revenue). For the full year FY2025, revenue was $1.07B (+12% year on year) and net income $391M. Its largest product in Q2 2026 was Nuplazid at $183M, 59% of the disclosed total, ahead of Daybue at 41%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 24, 2026On September 24, 2026, the Company announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with ADP. For the primary endpoint of change from baseline in the Scale for the …Regulation FD disclosure · Form 8-K
- Sep 11, 2026On August 24, 2026, the United States District Court for the Southern District of California (the “Court”) preliminarily approved the settlement (“Settlement”) of the stockholder derivative action captioned Kanner et al. v.Other event · Form 8-K
- Aug 4, 2026Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $308.0MThe company’s own SEC segment disclosure.
- Nuplazid$183.1M59%
- Daybue$124.8M41%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.